Instead, deregulation of Hh signaling in these malignancies, not unlike breast cancer, is likely due to multiple coexisting mechanisms of pathway activation comprising SMO‐dependent autocrine and/or paracrine signaling and SMO‐independent signaling through direct regulation of GLI expression or activity (Table 2). This evidence concerns the gene GLI1 and breast carcinoma.